Non-genomic progesterone actions in female reproduction

Gellersen, Birgit; Fernandes, Maria Sofia; Brosens, Jan J.

doi:10.1093/humupd/dmn044

Cited by 185 publications

(142 citation statements)

References 256 publications

Supporting

Mentioning

125

Contrasting

Unclassified

Order By: Relevance

“…Progesterone regulates the peri-implantation period and immune responses during pregnancy, but also suppresses uterine contractions during pregnancy, and initiates labor and cervical ripening at the end of pregnancy. In the human reproductive system, progesterone exerts its effects via genomic and non-genomic actions which converge to produce tissue-and cell-specific responses [12].…”

Section: Discussionmentioning

confidence: 99%

Does progesterone therapy increase nuchal translucency in women with threatened miscarriage?

Kececioglu

Tokmak²,

Kececioglu³

et al. 2016

Ginekol Pol

View full text Add to dashboard Cite

Objectives: The effect of exogenous progesterone on fetal nuchal translucency (NT) has been proposed recently. In this study, we aimed to compare the thickness of NT of patients receiving and not receiving progesterone for threatened miscarriage. Material and methods:This study was designed as a retrospective comparative study. Ninety five women treated with progesterone constituted the study group whereas 97 women who were not treated with progesterone constituted the control group. An ultrasonographic examination was performed on all of the women to measure NT. All patients were treated with oral micronized progesterone in the study group. The main parameters recorded for each woman were; age, body mass index (BMI), obstetrical characteristics, and gestational age at first examination, treatment duration of progesterone therapy, and results of combined and triple tests.Results: A total of 192 pregnant women with threatened miscarriage were included in this study. The mean NT thickness was statistically significantly higher in the study group (p < 0.001), and mean serum level of human chorionic gonadotropin (hCG) was also higher in this group (p < 0.05). There was no statistically significant difference between groups in terms of age, BMI, and gestational age at first examination. ROC curve analysis demonstrated that only increased NT (area under the curve: 0.634, p = 0.005, 95% CI: 0.541-0.727) was a discriminative factor for women receiving progesterone for threatened miscarriage. Also there was a positive correlation between NT and treatment duration (r = 0.269; p < 0.001). Conclusions:We think that oral progesterone therapy may increase NT depending on treatment duration without causing abnormal prenatal screening test results.

show abstract

Section: Discussionmentioning

confidence: 99%

Does progesterone therapy increase nuchal translucency in women with threatened miscarriage?

Kececioglu

Tokmak²,

Kececioglu³

et al. 2016

Ginekol Pol

View full text Add to dashboard Cite

show abstract

“…it possible, therefore, that mPrα requires an accessory protein that is expressed in tissue-or cell-specific manner, thus affecting its transport to the membrane. These studies highlight the difficulty in drawing any firm conclusions on 7TMR trafficking (30), and present an arguement for a higher order of complexity regarding mPrα distribution.…”

Section: Discussionmentioning

confidence: 80%

Internalisation of membrane progesterone receptor-α after treatment with progesterone: Potential involvement of a clathrin-dependent pathway

Karteris¹

2009

Mol Med Rep

View full text Add to dashboard Cite

Abstract. internalisation and recycling of seven transmembrane domain receptors is a critical regulatory event for their signalling. The mechanism(s) by which membrane progesterone receptor-α (mPrα) number is regulated on the cell surface is unclear. in this study, we investigated the cellular distribution of mPrα and mechanisms of mPrα trafficking using a cell line derived from a primary culture of human myometrial cells (M11) as an experimental model. rT-Pcr and immunofluorescent analysis demonstrated expression of mPrα in M11 cells with mPrα primarily distributed on the cell surface under basal conditions. For the first time, plasma membrane localisation of mPrα was confirmed using immunogold transmission electron microscopy. Stimulation of M11 cells with progesterone (P4, 100 nM) resulted in internalisation of mPrα from the plasma membrane to the cytoplasm (10 min) and subsequent limited translocation back to the cell surface (20 min). We investigated potential endocytotic pathways involved in trafficking of mPRα after its internalisation. Partial co-localisation of clathrin with mPrα was obvious after 10 min of P4 treatment. of note, chlorpromazine (inhibitor of clathrin-mediated pathway) inhibited the endocytosis of mPrα, whereas treatment with nystatin (inhibitor of caveolae-mediated pathway) did not affect internalisation. collectively, these data suggest that mPrα is expressed on the cell surface of M11 cells and undergoes endocytosis after P4 stimulation primarily via a clathrin-mediated pathway. IntroductionThe large group of seven transmembrane domain receptors (7TMRs) include the well-known superfamily of G protein coupled receptors (GPCRs) as well as the phylogenetically distinct family of membrane progesterone receptors (mPrs) (1,2). Trafficking of 7TMRs between the various cell compartments is crucial for their ligand-binding and signalling functions. internalisation of 7TMrs by endocytosis controls important receptor functions in the cell, fine tuning the binding characteristics of the receptor and regulating the activation of different signal transduction pathways. Some cell-surface receptors can also activate signal transduction pathways from intracellular compartments, suggesting that signalling can be regulated by compartmentalization (3).Internalisation of many GPCRs involves rapid clathrinmediated endocytosis (3-5). The agonist-occupied receptor is recruited into clathrin-coated pits (ccP), which then form vesicles for entry into the endocytic pathway. at this stage, vesicles and their cargo can be directed for either degradation or recycling back to the cell surface (6,7). For example, it has been shown that different internalisation routes seem to predetermine whether transforming growth factor β (TGF-β) receptors will trigger a signalling response or be degraded (3). The precise mechanisms influencing the fate of the CCPreceptor complex are not fully elucidated, but emerging data suggest that they are receptor specific and may vary between cell types (8). Another route by which GPCRs ca...

show abstract

“…Outside of the predicted protection from catamenial exacerbation of epileptic seizures and premenstrual dysphoric disorder by neurosteroids (Biagini et al, 2010), the non-genomic effects of progesterone in reproductive function in the female human have been less well characterised. Several other reported progesterone receptors (mPR, PGRMC1 and CatSper, for instance) have also been touted to contribute to the non-genomic effects of progesterone (Dressing et al, 2011;Gellersen et al, 2009;Lishko et al, 2011;Zhu et al, 2003). Based on expression data and some functional characterisation both mPR and PGRMC1 may have a role in reproductive function and are speculated to regulate implantation and myometrial contractility.…”

Section: Progesterone Receptor Structure and Functionmentioning

confidence: 99%

Progesterone Resistance and Targeting the Progesterone Receptors: A Therapeutic Approach to Endometriosis

Pullen¹

2012

Endometriosis - Basic Concepts and Current Research Trends

View full text Add to dashboard Cite

Non-genomic progesterone actions in female reproduction

Cited by 185 publications

References 256 publications

Does progesterone therapy increase nuchal translucency in women with threatened miscarriage?

Does progesterone therapy increase nuchal translucency in women with threatened miscarriage?

Internalisation of membrane progesterone receptor-α after treatment with progesterone: Potential involvement of a clathrin-dependent pathway

Progesterone Resistance and Targeting the Progesterone Receptors: A Therapeutic Approach to Endometriosis

Contact Info

Product

Resources

About